Lupin launches generic AndroGel
Lupin is launching testosterone gel, 1.62% (20.25 mg/1.25 g pump actuation).
Lupin's product is the generic of AbbVie's AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
Testosterone gel, 1.62% (20.25 mg/1.25 g pump actuation) had a market value of approximately $893 million, according to December 2018 IQVIA data.
Lupin's product is the generic of AbbVie's AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
Testosterone gel, 1.62% (20.25 mg/1.25 g pump actuation) had a market value of approximately $893 million, according to December 2018 IQVIA data.